Method for treating pervasive development disorders

Patent metadata

Field	Value
Publication number	US-9624526-B2
Application number	US-201113313708-A
Country	US
Kind code	B2
Filing date	Dec 7, 2011
Priority date	Dec 17, 1999
Publication date	Apr 18, 2017
Grant date	Apr 18, 2017

Abstract

A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. A method for determining the efficacy of neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with neuropeptides, peptides, or digestive enzyme administration.

First claim

The invention claimed is:

1. A method for treating an individual having an autistic disorder, the method comprising measuring a level of fecal chymotrypsin in a sample from the individual and administering to the individual three or more doses per day of an effective amount of digestive enzymes if the individual has a subnormal level of fecal chymotrypsin to promote changes in autistic behavior by ameliorating a symptom of the autistic disorder, wherein the digestive enzymes comprise a protease, an amylase and a lipase.

2. The method of claim 1 , wherein the symptom comprises an impairment in making eye contact with another individual.

3. The method of claim 1 , wherein the symptom comprises a lack of social interaction.

4. The method of claim 1 , wherein the symptom comprises a delay in, or lack of, spoken language.

5. The method of claim 1 , wherein the symptom comprises a repetitive pattern of behavior such as arm flapping.

6. The method of claim 1 , wherein the symptom comprises hyperactivity.

7. The method of claim 1 , wherein the symptom comprises a lack of a formed bowel movement.

8. The method of claim 1 , wherein the symptom comprises a lack of toilet training.

9. The method of claim 1 , wherein the method comprises administering digestive enzymes comprising approximately 4,000 to approximately 60,000 United States Pharmacopeia (U.S.P.) Units/tablet on a daily basis.

10. The method of claim 1 , wherein the digestive enzymes further comprise a cellulase, a sucrase, or a maltase, either singularly or in any combination thereof.

11. The method of claim 1 , wherein the method comprises administering an amount of digestive enzymes on a daily basis, wherein said amount is determined according to the age of the individual.

12. The method of claim 1 , wherein the digestive enzymes comprise pancreatic enzymes.

13. The method of claim 1 , wherein the protease comprises trypsin or chymotrypsin.

14. The method of claim 1 , wherein the level of fecal chymotrypsin is measured by an enzymatic spectrophotometry method.

15. The method of claim 1 , wherein administration of the digestive enzymes improves protein digestion.

Assignees

• Fallon Joan M
• Curemark Llc

Inventors

• Fallon Joan M

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C12Q1/37 Primary

  involving peptidase or proteinase · CPC title

• A61P1/18

  for pancreatic disorders, e.g. pancreatic enzymes · CPC title

• A61B5/4848

  Monitoring or testing the effects of treatment, e.g. of medication · CPC title

• C12Y304/21004

  Trypsin (3.4.21.4) · CPC title